Abstract 3337
Background
Family caregivers of cancer patients report high burden leading to poor emotional and physical health. Knowledge of predisposing factors could contribute to its prevention or early detection. The aim of this study was to identify the factors related to caregiver burden among caregivers of cancer patients.
Methods
90 cancer patients hospitalised in two oncological wards in Crete, Greece and their primary caregivers (PCs) were included in the study. They both provided their demographics, while PCs completed the Bakas Caregiving Outcomes Scale (BCOS), comprising 15 self-rated items (7-point response scale with reduced BCOS scores implying higher burden) and the Hospital Anxiety and Depression Scale (HADS), comprising 14 self-rated items in a 4-point scale (0-3).
Results
Most patients were male (52.2%) and most PCs were female (67.8%), aged 50 to 74 years old (52.2% and 54.4% respectively). The majority of PCs (44.3%) were spouses. The mean of burden using the BCOS was 56.7 (SD 10.9) (range 22-100), 75.6% experienced no burden (total score > 52.5), while 24.4% reported high burden (total score < 52.5). High level of anxiety (≥ 11) using the HADS was reported by 55.6% of PCs and high level of depression (≥ 11) by 20%. The correlations between BCOS and HAD-Anxiety (r=-0.401, p < 0.001) and BCOS and HAD-Depression (r=-0.402, p < 0.001) were negatively moderate. Older age PCs appear to experience higher burden (r=-0.278, p = 0.008) and depression (r = 0.372, p < 0.001), while the duration of caregiving also imposes more anxiety (r=-0.322, p = 0.002) and depression (r = 0.262, p = 0.013). On the other hand, depression correlates negatively with the educational background of both patients (r=-0.247, p = 0,019) and caregivers (r=-0.283, p = 0.007).
Conclusions
Primary caregiver anxiety, depression, age, the duration of caregiving and the patient and caregiver educational background are factors related to caregiver burden. Larger sample studies are needed to better identify the factors affecting caregiver burden.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1707 - Clinical utility of precision immunoprofiling and monitoring of the tumor microenvironment using flow cytometry and CyTOF in patients with advanced NSCLC treated with atezolizumab: results from a phase II study for biomarker analysis (EPOC1702)
Presenter: Keisuke Kirita
Session: Poster Display session 3
Resources:
Abstract
3594 - Tumor mutation burden (TMB), PD-L1, IFN-γ signaling identify subgroups of patients (pts) who benefit from durvalumab (D, anti-PDL1) or D and tremelimumab (T, anti-CTLA4) treatment in urothelial bladder cancer (UC)
Presenter: Christophe Massard
Session: Poster Display session 3
Resources:
Abstract
744 - The decrease of TMB, TNB and HLA expression are the Mechanism of Drug Resistance of NSCLC to immunosuppressive PD-1/PD-l1.
Presenter: Sheng Yu
Session: Poster Display session 3
Resources:
Abstract
2350 - Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) predicts succeeding onset of immune-related adverse events (irAEs)
Presenter: Rika Kizawa
Session: Poster Display session 3
Resources:
Abstract
5930 - A transcriptomic immunologic signature predicts favorable outcome in neoadjuvant chemotherapy treated triple negative breast tumors.
Presenter: Javier Pérez-peña
Session: Poster Display session 3
Resources:
Abstract
6127 - Alterations of TMB and TCR repertoires during Chemotherapy in East Asian lung cancer patients without TKI-related driver gene mutations
Presenter: Lele Song
Session: Poster Display session 3
Resources:
Abstract
1310 - Association of SCFA in gut microbiome and clinical response in solid cancer patients treated with andi-PD-1 antibody.
Presenter: Motoo Nomura
Session: Poster Display session 3
Resources:
Abstract
2286 - Extracellular matrix and tissue derived metabolites in a liquid biopsy identifies endotypes of metastatic melanoma patients with differential response to immune checkpoint inhibitor treatment
Presenter: Nicholas Willumsen
Session: Poster Display session 3
Resources:
Abstract
4107 - Pathologic scoring of pre-treatment H&E biopsies predicts overall survival in patients with metastatic clear cell renal cell carcinoma receiving nivolumab monotherapy
Presenter: Julie Stein
Session: Poster Display session 3
Resources:
Abstract
1291 - PD-L1 expression in uncommon EGFR-mutant non-small cell lung cancer and its response to immunotherapy
Presenter: Yun Fan
Session: Poster Display session 3
Resources:
Abstract